Sheets Smith Investment Management’s AbbVie ABBV Stock Holding History

Sheets Smith Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$520K	Buy	+2,246	New	+$457K	0.34%	84

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sheets Smith Investment Management's ABBV Position: Q3 2025 in Review

Sheets Smith Investment Management opened a new position in AbbVie (ABBV) in Q3 2025: 2,246 shares worth $520K. The stake represents 0.34% of the portfolio and ranks #84 among its holdings.

3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

Sheets Smith Investment Management held 2,246 shares of AbbVie worth $520K as of Q3 2025.
AbbVie was a new Sheets Smith Investment Management position in Q3 2025.
AbbVie made up 0.34% of Sheets Smith Investment Management's portfolio in Q3 2025, its #84 holding.
3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Sheets Smith Investment Management's 13F filing for Q3 2025, filed 8 Oct 2025.